Challenges for Australia's bio/nanopharma policies: Trade deals, public goods and reference pricing in sustainable industrial renewal

Australia and New Zealand Health Policy

Volumn 4, Issue 1, 2007, Pages

  Faunce, Thomas A ^a  

^a The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ATORVASTATIN; BRCA1 PROTEIN; CLOPIDOGREL; CYTOCHROME P450; FELODIPINE; GENERIC DRUG; HEPATITIS B VACCINE; HUMAN GROWTH HORMONE; LOPINAVIR PLUS RITONAVIR; MACROGOL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMEPRAZOLE; PEGINTERFERON; RANITIDINE; SIMVASTATIN; VIVAGEL;

ARTICLE; AUSTRALIA; BIOTECHNOLOGY; BREAST CANCER; CHINA; COMMERCIAL PHENOMENA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GENETIC SCREENING; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INVESTMENT; MEDICAL ETHICS; MEDICAL INSTRUMENTATION; NANOTECHNOLOGY; PATENT; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE PRICING; PUBLIC HEALTH SERVICE; UNITED STATES;

EID: 34347407380     PISSN: 17438462     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-8462-4-9     Document Type: Article

References (103)

1. Economist Intelligence Unit Benchmarking Study of the Characteristics of the Australian and International Pharmaceuticals Industry. Australian Government. Dept. of Industry, Tourism and Resources. Canberra 2005
2. Anonymous Generics Makers Slam PBS Reforms Pharma in Focus 17 November 2006.
3. Lofgren H Generic Drugs: International Trends and Policy developments in Australia. Working paper 10. Centre for Strategic Economic Studies. Melbourne 2002
4. Gray N Changing Landscape: A Special Report on the World's Top 50 Pharma Companies Pharmaceutical Executive 2006 78-88
5. Business Monitor Australia Pharmaceuticals and Healthcare Report http://www.pharmainfocus.com.au/news.asp?newsid=1143 (last accessed 8 May 2006)
6. Productivity Commission 2001 International Pharmaceutical Price Differences: Research Report. Ausinfo Canberra 2001
7. Sweeny K Review of Findings: Australian Pharmaceutical Pricing in a Global Context, Working Paper No. 19, Centre for Strategic Economic Studies, Victoria University, Melbourne 2004
8. Neville W Unpublished PhD Thesis 2007 Globalisation and Health Project. Centre for Governance of Knowledge and Development, Regulatory Institutions Network, Australian National University
9. Sansom L The subsidy of pharmaceuticals in Australia: Process and challenges Australian Health Review 2004 28 2 194-205 15527399
10. Ioannides-Demos L Ibrahim J McNeil J Reference-Based Pricing Schemes: Effect on Pharmaceutical Expenditure, Resource Utilisation and Health Outcomes. Review Article Pharmacoeconomics 2002 20 9 577-591 10.2165/ 00019053-200220090-00002 12141886
11. Lipsy RJ Institutional formularies: The relevance of pharmacoeconomic analysis to formulary decisions Pharmacoeconomics 1992 1 4 265-81 10147017
12. Jacobzone S Pharmaceutical policies in OECD countries: Reconciling social and industrial goals. Paris, OECD. DEELSA/ELSA/WD (2000)1 2000
13. Giuliani G Selke G Garattini L The German Experience in Reference Pricing Health Policy 1998 44 1 73-85 10.1016/S0168-8510(98)00012-8 10180203
14. Commonwealth of Australia. National Medicines Policy http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ nmp-objectives-policy.htm (last accessed 6 Feb 2007)
15. Australian Government, Department of Industry, Tourism and Resources Pharmaceuticals Industry Action Agenda http://www.industry.gov.au (last accessed 22 Oct 2006)
16. Pharmaceutical Industry Investment Program (PIIP) 1999-2004 http://www.industry.gov.au/content/itrinternet/cmscontent.cfm?objectID= FDBCC43B-898E-4433-AFCA84E5DF7D417D
17. Medicare Prescription Drug Improvement and Modernization Act 2003 21 U.S.C. conference agreement House Report 108-391 Title XI-Access to Pharmaceuticals http://thomas.loc.gov/cgi-bin/cpquery/?&db_id= mp;r_n=hr391.108&sel=TOC_2588886& [accessed 11 February 2005] Trade Act 2002 (US), 107-210 §2102 (b) (8) (D).
18. Deady S Special Negotiator, Office of Trade Negotiations. Dept. Foreign Affairs and Trade. Senate Select Committee on the Free Trade Agreement between Australia and the United States of America; 16 Official Committee Hansard Monday 21 June 2004 16 http://www.aph.gov.au/Senate/ committee/freetrade_ctte/hearings/index.htm (last accessed 1 Feb 2007)
19. Deady S Special Negotiator, Office of Trade Negotiations. Dept. Foreign Affairs and Trade. Senate Select Committee on the Free Trade Agreement between Australia and the United States of America Official Committee Hansard Monday 21 June 2004; 12 and 16 http://www.aph.gov.au/Senate/ committee/freetrade_ctte/hearings/index.htm (last accessed 1 Feb 2007)
20. Lopert R Medical Adviser, Pharmaceutical Benefits Brach, Dept. Health and Ageing. Senate Select Committee on the Free Trade Agreement between Australia and the United States of America Official Committee Hansard Monday 21 June 2004; 18, 19, 24 http://www.aph.gov.au/Senate/committee/ freetrade_ctte/hearings/index.htm (last accessed 1 Feb 2007)
21. Faunce T Senate Select Committee on the Free Trade Agreement between Australia and the United States of America Official Committee Hansard Monday 21 June 2004; 56 http://www.aph.gov.au/Senate/committee/ freetrade_ctte/hearings/index.htm (last accessed 1 Feb 2007)
22. Faunce TA Henry D Drug Lobby Preparing a Bitter Pill The AgeBalan. 2006 12311599
23. Interviews conducted by the author and Professor Peter Drahos with the major Australian generic pharmaceutical companies in 2005 under an Australian Research Council grant
24. Anonymous Never Again Says Abbott on 12.5% Pharma in Focus 25 September 2006
25. Commonwealth of Australia National Medicines Policy http://www.health.gov.au/internet/wcms/Publishing.nsf/ Content/National+Medicines+Policy-2 (last accessed 1 Feb 2007)
26. Document 14 Pharmaceutical Benefits Pricing Authority Matters obtained under Freedom of Information application. Dr Patricia Ranald, Principal Policy Officer Public Interest Advocacy Centre 2007
27. Interviews by the author in 2005 with members of the PBAC under an Australian Research Council grant
28. Abbott Tony Federal Minister for Health. PBS Consultation Media Release 17 May 2006
29. Stafford A Industry says PBS option good medicine The Financial Review 23 Feb 2006: 27
30. Costello P Q&A Session, National Press Club http://www.treasurer.gov.au/tsr/content/transcripts/2006/021.asp 1 March 2006, (last accessed 3 April 2006)
31. Medicines Australia Media Release, Warning to Government Form Biotech on PBS Changes http://www.medicinesaustralia.com.au/pages/page87.asp 30 January 2006, (last accessed 3 April 2006)
32. Tassone, Anthony 2006 Generic Tendering - Is This the Road to Damascus?' i2p (Information to Pharmacists) 46 http://i2p.com.au/?page=site/ article&id=389 (last accessed 3 April 2006)
33. Anonymous Delaat to call for PBS reform Pharma in Focus 18 July 2005.
34. Vaile M Deputy Prime Minister and Minister for Trade, Joint press conference at the office of the United States Trade Representative, Washington DC, 7 March
35. Organised by Pat Ranald. Australian Fair Trade and Investment Network 2007
36. Andrew Laming 2006 "Let's Overhaul the Pharmaceutical Benefits Scheme' 10 January The Australian 10
37. Australian Government Dept. of Health and Ageing PBS Reform http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ pbs_reform_02feb07.htm (last accessed 3 May 2007).
38. Australian Government. Depart. Health and Ageing http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ Strengthening-your-PBS.htm (last accessed 3 Feb 2007)
39. Abbott T Hon Australian Minister for Health. Press Conference - PBS reform Commonwealth Parliamentary Offices, Sydney http://www.health.gov.au/internet/ministers/publishing.nsf/Content/ health-mediarel-yr2006-ta-abb161106.htm 16 Nov 2006 (last accessed 25 Jan 2007)
40. Anonymous Generics makers slam PBS Reforms Pharmain Focus 17 Nov 2006.
41. Comments by panellists and speakers Australian Government Attorney-General's Department, Internatioal Trade law Symposium 4 May 2007 University House, Australian National University
42. Faunce TA Lofgren H Harvey K Johnston K Tendering for Low Cost Generics in Australia Health Issues 2006 87 26-29
43. Lofgren Hans Generic drugs: International trends and policy developments in Australia Australian Health Review 2004 27 1 39-48 15362295
44. Anonymous Alphapharm could go to Ranbaxy Pharma in Focus 15 Jan 2007.
45. Anonymous Sigma and Arrow announce merger Pharma in Focus 22 August 2005.
46. Anonymous New generic player on the blocks Pharma in Focus 13 Feb 2006.
47. Economist Intelligence Unit Benchmarking Study of the Characteristics of the Australian and International Pharmaceuticals Industry. Sept 2005. Australian Government. Dept. of Industry, Tourism and Resources 18
48. Probyn Andrew A Some drugs more equal than others: Pseudo-generics and commercial practice', Australian Health Review 2004 28 2 207-217 15527401
49. Hollis Andrew The Anti-Competitive Effects of Brand-Controlled "Pseudo-Generics" in the Canadian pharmaceutical market Canadian Public Policy 2003 29 1 21-32
50. Lawrence S Biotech Patenting Upturn Nature Biotechnology 2007 24 10 1190 10.1038/nbt1006-1190
51. Economist Intelligence Unit. Benchmarking Study of the Characteristics of the Australian and International Pharmaceuticals Industry. Sept 2005. Australian Government. Dept. of Industry, Tourism and Resources Lofgren H Benner M Biotechnology and Governance in Australia and Sweden: Path Dependency or Institutional Convergence Australian Journal of Political Science 2003 38 1 25-43 10.1080/1036114032000056233
52. Dove A Betting on biogenerics Nature Biotechnology 2001 19 117-120 10.1038/84365 11175723
53. Owens J 2006 drug approvals: Finding the niche Nature Reviews Drug Discovery 2007 6 99-101 10.1038/nrd2247 17342860
54. Vastg B The Policy Outlook from the Hill Nature Biotechnology 2007 25 1 13-16 10.1038/nbt0107-13 17211381
55. Heuser S European decision presages era of generic biology drugs Boston Globe http://www.boston.com/business/healthcare/articles/2006/02/13/ european_decision_presages_era_of_generic_biology_drugs/ February 13, 2006, (last accessed 1 Feb 2007)
56. Moran N Danish biotech outperforms its European counterparts Nature Biotechnology 2006 24 1460-1461 10.1038/nbt1206-1460 17160030
57. Lazarou J Pomeranz BH Corey PN Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies JAMA 1998 279 1200-1205 10.1001/jama.279.15.1200 9555760
58. Weber WW Pharmacogenetics Oxford University Press; Oxford 1997
59. Wolf CR Smith G Smith RL Pharmacogenetics BMJ 2000 320 7240 987-990 1117913 10753155 10.1136/bmj.320.7240.987
60. Sone J Fujita J Ochiai Y Manako S Matsui S Nomura E Baba T Kawaura H Sakamoto T Chen CD Nakamura Y Tsai JS Nanofabrication toward sub-10 nm and its application to novel nanodevices Nanotechnology 1999 10 135-141 10.1088/0957-4484/10/2/306
61. Brower V Is Nanotechnology Ready for Primetime? J Natl Cancer Inst 2006 98 1 9-11 16391365
62. Wagner V Dullart A Bock A-K Zweck A The emerging nanomedicine landscape Nature Biotechnology 2006 24 10 1211-1218 10.1038/nbt1006-1211 17033654
63. Ghadiri MR Antibacterial Agents Based on the Cyclic D, L Peptide Architecture Nature 2001 412 451-455
64. Bottini M Bruckner S Nika K Bottini N Bellucci S Magrini A Bergamaschi A Mustelin T Multi-Walled Carbon Nanotubules Induce T Lymphocyte Apoptosis Toxicology Letters 2006 160 121-126 10.1016/j.toxlet.2005.06.020 16125885
65. Leary SP Liu CY Yu C Apuzzo MLJ Toward the Emergence of Nanoneurosurgery: Part I-Progress in Nanoscience, Nanotechnology and the Comprehension of Events in the Mesoscale Realm Neurosurgery 2005 57 4 606-633 10.1227/01.neu.0000181533.17956.f9 16239874
66. Kong DF Goldschmidt-Clermont PJ Tiny Solutions for Giant Cardiac Problems Trends Cardiovasc Med 2005 15 6 207-11 10.1016/ j.tcm.2005.07.003 16182130
67. Hulstein JJ de Groot PG Silence K Veyradier A Fijnheer R Lenting PJ A Novel Nanobody that Detects the Gain-of-function Phenotype of von Willebrand Factor in ADAMTS13 Deficiency and von Willebrand Disease Type 2B Blood 2005 106 9 3035-42 10.1182/blood-2005-03-1153 16014562
68. Prestidge CA Nanoscience facilitating the development of novel pharmaceutical delivery systems Abstract of oral presentation Australian Research Council Nanotechnology Network International Conference on Nanoscience and Naotechnology Brisbane Convention Centre 3-7 July 2006
69. Australian Academy of Science Nanotechnology Benchmarking Project http://www.science.org.au/policy/nano-exec.htm [last accessed 28 Jan 2006]
70. Institute of Occupational Medicine for the Health and Safety Executive Nanoparticles: An Occupational Hygiene Review 2004 http://www.hse.gov.uk [last accessed 14 Aug 2006]
71. Department of Employment and Workplace Relations Australian Government Submission to Senate Inquiry Into Workplace Exposure to Toxic Dusts and Nanoparticles Canberra August 2005
72. Flinders Consulting Pty Ltd. A review of the potential occupational health and safety implications of nanotechnology Australian Safety and Compensation Council 2006 http://www.ascc.gov.au/ascc/AboutUs/ Publications/ResearchReports/AReviewofthePotentialOccupational HealthandSafetyImplicationsofNanotechnology.htm
73. Baluch AS Angstrom Medica: Securing FDA approval and commercializing a nanomedical device Nanotechnology Law and Business 2005 2 168-173
74. Till MC Simkin MM Maebius S Nanotech meets the FDA: A success story about the first nanoparticlate drugs approved by the FDA Nanotechnology Law and Business 2005 2 163-167
75. Faunce TA Walters H Williams T Bryant D Jennings M Musk B Policy challenges from the "White" Senate inquiry into workplace-related health impacts of toxic dusts and nanoparticles Aust New Zealand Health Policy 2006 3 7 1513237 16780594 10.1186/1743-8462-3-7
76. Homer JB Hirsch GB System Dynamics Modeling for Public Health: Background and Opportunities AJPH pre-published Jan 31 2006, 10.2105/ AJPH.2005.062059.
77. European Science Foundation Nanomedicine: An ESF-European Medical Research Councils (EMRC) Forward Look Report (European Science Foundation, Strasbourg 2005)
78. Australian Government. Invest Australia Australian Nanotechnology. Capability and Commercial Potential 2nd ed Cth Australia 2005 2005
79. Maskus KE JH Reichman The Globalisation of private knowledge goods and the privatisation of global public goods in KE Maskus and JH Reichman (2005) International Public Goods and Transfer of Technology Under a Globalised Intellectual Property Regime Cambridge University Press, NY 2005 3-45
80. World Trade Organisation Declaration on the TRIPS agreement and public health WT/MIN(01)/DEC/2 20 November 2001.
81. UNESCO Universal Declaration on Bioethics and Human Rights http://portal.unesco.org/shs/en/ev.php-URL_ID=1883&URL_DO= DO_TOPIC&URL_SECTION=201.html last accessed 12 Dec 2005.
82. Kaul I Financing Global Public Goods: Challenges. In von Weisacker EU, Young OR and Finger M Limits to Privatisation. How to Avoid Too Much of a Good Thing? 2006 311
83. Faunce TA Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public good Globalization and Health 2006 2 5-15 http://www.globalizationandhealth.com/content/2/1/5 10.1186/ 1744-8603-2-5
84. Boseley S Scientists on a mission to bring cheap drugs to the world's poorest Countries The Guardian January 2, 2007
85. China Economic Information and Agency The Internal and External Environments Facing the Domestic Pharmaceutical Industry. Beijing 2002
86. Faunce TA Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public good Globalization and Health 2006 2 5-15 http://www.globalizationandhealth.com/content/2/1/5 10.1186/1744-8603-2-5
87. Commonwealth Government. Department of Foreign Affairs and Trade. Australia-China Free Trade Negotiations http://www.dfat.gov.au/geo/china/fta/ (last accessed 6 Feb 2007)
88. Faunce TA Johnston K Bambrick H The Australia-New Zealand Therapeutic Products Agency: Potential Impacts on Safety and Cost-Effectiveness Regulation for Medicines and Medical Devices Victoria University of Wellington Law Review 2006 37 3 365-390
89. Faunce T Doran E Henry D Drahos P Searles P Pekarsky B Neville W Assessing the Impact of the Australia-United States Free Trade Agreement on Australian and Global Medicines Policy Glob and Health 2005 1 1-15 10.1186/1744-8603-1-1
90. Medical Services Advisory Committee Performance Report 2003-05 DOHA, Canberra 2005
91. Discussions between the author and senior South Korean medicines regulatory officials, prior to and during the KORUSFTA negotiations
92. Office of the US Trade Representative. Korea-United States Free Trade Agreement Chapter Five. Pharmaceutical and Medical Devices http://www.ustr.gov/Trade_Agreements/Bilateral/Republic_of_Korea_FTA/ Draft_Text/Section_Index.html (last accessed 26 May 2007)
93. Minhas R Moon JC The Office of Fair Trading report: a prescription for value-based drug pricing Journal of the Royal Society of Medicine 2007 100 216-18 1861417 17470928 10.1258/jrsm.100.5.216
94. Wilsensky G Developing a center for comparative effectiveness information Health Affairs Web Exclsuive 2006 w572-84 10.1377/ hlthaff.25.w572
95. Jackson RJ Ramsay AJ Christensen CD Beaton S Hall DF Ramshaw IA Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox J Virol 2001 75 1205-1210 114026 11152493 10.1128/ JVI.75.3.1205-1210.2001
96. Wein LM Liu Y Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk Proc Natl Acad Sci USA 2005 102 9984-9989 1161865 15985558 10.1073/pnas.0408526102
97. Taubenberger JK Reid AH Lourens RM Wang R Jin G Fanning TG Characterization of the 1918 influenza virus polymerase genes Nature 2005 437 889-893 10.1038/nature04230 16208372
98. Tumpey TM Basler CF Aguilar PV Zeng H Solórzano A Swayne DE Cox NJ Katz JM Taubenberger JK Palese P García-Sastre A Characterization of the reconstructed 1918 Spanish influenza pandemic virus Science 2005 310 77-80 10.1126/science.1119392 16210530
99. von Bubnoff A The 1918 flu virus is resurrected Nature 2005 437 794-795 10.1038/437794a 16208326
100. Bambrick H Faunce T Johnston T AUSFTA ands safety of Australia's blood supply Medical Journal of Australia 2006 185 6 320-323 16999673
101. Flood P Wills P Lawler P Ryan G Rickard KA Review of Australia's Fractionation Arrangements. Canberra: Commonwealth of Australia 2006
102. Hill J Kirchner A Holmes A Pharmaceuticals Industry Action Agenda. Discussion Paper http://www.isr.gov.au/agendas/Sectors/Pharmaceuticals; [last accessed 22.3.05]
103. Hill J Kirchner A Holmes A Pharmaceuticals Industry Action Agenda. Discussion Paper http://www.isr.gov.au/agendas/Sectors/Pharmaceuticals [last accessed 22.3.05]